Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name SLC6A9-5:2
   Synonyms SLC6A9, GCENSG, GLYT1
   Region NA    Sequence
   Ensembl NA
   RefSeq NA
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name papillary thyroid cancer
   ICD-0-3  M8260/3
   Methods microarray, qPCR, RNAi, Western blot, Luciferase reporter assay, Cell proliferation assay etc.
   Sample PTC tissues, cell lines (TPC-1 and BCPAP)
   Expression Pattern down-regulated
   Function Description

We demonstrated that SLC6A9-5:2 was remarkably downregulated in 131I-resistant thyroid cancer cell lines and 131I-insensitive patients and was positively correlated with Poly (ADP-ribose) polymerase 1 (PARP-1) expression and its activation. After downregulating SLC6A9 or blocking PARP-1 artificially, the sensitive thyroid cancer cells mostly displayed a tolerant phenotype under 131I exposure. Furthermore, SLC6A9-5:2 overexpression was positively correlated with PARP-1 mRNA and protein levels, which restored the sensitivity of resistant thyroid cancer cells.

   Pubmed ID 28086241
   Year 2017
   Title LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.
   External Links
   Links for  SLC6A9-5:2 GenBank       HGNC       lncrnadb       Noncode
   Links for  papillary thyroid cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.